查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015061

多模態成像市場：按組件、模態、應用和最終用戶分類 - 2026-2032年全球市場預測

Multimodal Imaging Market by Component, Modality, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，多模態成像市場價值將達到 33.6 億美元，到 2026 年將成長至 35.8 億美元，到 2032 年將達到 53.1 億美元，複合年成長率為 6.72%。

主要市場統計數據
基準年 2025 33.6億美元
預計年份：2026年 35.8億美元
預測年份 2032 53.1億美元
複合年成長率 (%) 6.72%

本文提出了一個教科書式的框架，概述了多模態成像的發展趨勢和臨床重點，為相關人員做出投資和營運決策提供了指南。

多模態影像技術正處於技術創新與臨床需求的交會點，重塑整體醫學領域的診斷流程與調查方法。近年來，分子影像與解剖成像的融合、先進的軟體分析以及整合服務模式的發展，為提高診斷信心、實現個人化治療方法選擇和簡化臨床工作流程創造了機會。本導言概述了貫穿本報告的關鍵主題：技術融合、臨床效用、監管變化以及影響技術普及的商業性趨勢。

概述推動多模態成像技術引入和重塑臨床工作流程的關鍵技術、監管和商業性轉折點。

多模態成像領域正經歷一場變革，其驅動力包括技術創新、對更精準診斷日益成長的需求以及數據驅動解讀作用的不斷擴大。高解析度檢測器、緊湊型多模態掃描儀和混合系統等硬體的改進，使臨床醫生能夠在單次掃描中獲得更豐富的資料集。同時，從人工智慧影像重建和定量生物標記到整合式PACS工作流程等軟體技術的進步，正在帶來新的診斷見解，並減少影像解讀的差異性。

本文探討了近期美國關稅趨勢如何促使醫療影像領域的供應鏈重組、籌資策略調整和策略採購。

關稅政策的改變會為全球醫療設備供應鏈帶來顯著的摩擦，推高採購成本，並迫使企業調整籌資策略。在美國，近期關稅調整已影響影像硬體、組件和配件的進口決策，促使製造商重新評估生產基地、供應商合約和庫存管理。此類政策變化往往會加速關於近岸外包、區域製造中心和雙重採購策略的討論，旨在降低貿易相關成本波動的影響。

透過使用將元件、模式、應用程式和最終用戶概況連結起來的綜合細分觀點，我們發現了差異化的部署路徑和價值來源。

詳細的細分分析揭示了從多個分析觀點審視市場時，需求促進因素和實施考量的差異。基於組件，市場研究分為硬體、服務和軟體三個領域。這種分類突顯了清晰的投資週期和採購行為，因為對先進硬體的資本投資與基於服務和軟體許可的持續收入模式並存。在硬體決策中，處理能力、影像品質和整合相容性是優先考慮的因素，而對服務和軟體的投資則著重於生命週期支援、分析能力以及與臨床IT系統的互通性。

一項區域分析概述了美洲、歐洲、中東和非洲以及亞太地區的醫療保健結構和政策環境如何產生不同的實施模式和夥伴關係模式。

區域趨勢在多模態影像生態系統中，對技術採納、報銷政策以及戰略夥伴關係的建立起著至關重要的作用。在美洲，市場結構通常體現為先進的三級醫療機構推動臨床創新，以及區域影像網路最佳化服務取得和吞吐量的結合。投資重點往往取決於報銷模式、醫院整合趨勢以及診斷中心的興起，這些診斷中心集中提供高成本影像服務，以提高使用率和實證醫學證據的產生。

從策略角度概述了成熟供應商和敏捷專家如何透過整合硬體、軟體和服務模式來競爭，從而提供臨床和商業性價值。

多模態成像領域的競爭格局呈現出成熟平台供應商與新興專業廠商並存的趨勢，這些廠商專注於檢測器設計、重建演算法和臨床軟體方面的創新。主要企業正投資於整合解決方案，這些方案融合了強大的硬體效能、先進的分析能力和雲端服務，而新參與企業則傾向於透過模組化、成本效益或創新的人工智慧驅動功能來脫穎而出。醫療設備製造商、軟體開發商和臨床網路之間的策略合作日益普遍，加速了整合解決方案的檢驗和部署。

為供應商、服務提供者和投資者提供實用的策略指導，以優先考慮經營模式。

產業領導者應將創新重點與臨床影響相結合，並專注於診斷準確性、工作流程效率和患者體驗方面的可衡量改進。投資決策必須平衡資本資產的績效與軟體平台和服務生態系統的長期價值，以實現持續改善和擴充性。與領先的學術機構和臨床試驗網路建立合作關係，能夠加速證據的產生，並促進監管部門更快地批准相關核准，以及與保險公司的合作。

我們將以透明的方式解釋我們的多來源研究途徑，該方法結合了臨床訪談、技術文獻和監管分析，以確保整合可靠的證據。

本研究採用多方面調查方法，整合了技術文獻綜述、政策法規分析以及與臨床和商業相關人員的定性訪談。關鍵見解來自與影像專家、醫院採購經理和服務供應商的結構化討論，並輔以說明臨床性能和部署結果的同行評審研究的回顧。二級資訊來源包括監管指導文件、技術白皮書和供應商技術規範，這些資料用於檢驗有關設備功能和互通性的說法。

簡潔的整合強調互通性、臨床檢驗和策略夥伴關係，認為這是多模態影像長期成功的關鍵支柱。

總之，關鍵訊息可概括如下：多模態成像正發展成為一個具有重要臨床意義且商業性前景廣闊的領域，需要硬體、軟體和服務的協同創新。能夠提供可量化的臨床效用、提高工作流程效率並與更廣泛的醫療保健IT生態系統整合的技術將推動其應用。同樣重要的是，要建立切實可行的經營模式和夥伴關係關係，以促進循證實踐、培訓和永續的資金籌措，從而在各種醫療保健環境中推廣應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：多模態影像市場：依組件分類

  • 硬體
  • 服務
  • 軟體

第9章：多模態影像市場：依模態分類

  • PET-CT
  • PET-MR
  • SPECT-CT

第10章：多模態影像市場：依應用分類

  • 循環系統
  • 神經病學
  • 腫瘤學

第11章：多模態影像市場：依最終用戶分類

  • 學術機構
  • 診斷影像中心
  • 醫院
  • 研究機構

第12章：多模態影像市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：多模態影像市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：多模態影像市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國多模態影像市場

第16章：中國多模態影像市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bruker Corporation
  • Canon Medical Systems Corporation
  • Carl Zeiss AG
  • Fujifilm Holdings Corporation
  • General Electric Company
  • Koninklijke Philips NV
  • Mediso Medical Imaging Systems Ltd.
  • MR Solutions Ltd.
  • PerkinElmer, Inc.
  • Siemens Healthineers AG
  • United Imaging Healthcare Co., Ltd.
Product Code: MRR-036C5CF3A88B

The Multimodal Imaging Market was valued at USD 3.36 billion in 2025 and is projected to grow to USD 3.58 billion in 2026, with a CAGR of 6.72%, reaching USD 5.31 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.36 billion
Estimated Year [2026] USD 3.58 billion
Forecast Year [2032] USD 5.31 billion
CAGR (%) 6.72%

An authoritative framing of multimodal imaging developments and clinical priorities to orient stakeholders toward investment and operational decision points

Multimodal imaging sits at the intersection of technological innovation and clinical need, reshaping diagnostic pathways and research methodologies across medicine. In recent years, the convergence of molecular and anatomical imaging modalities, advanced software analytics, and integrated service models has created opportunities to enhance diagnostic confidence, personalize therapy selection, and streamline clinical workflows. This introduction frames the essential themes that run through the report: technological convergence, clinical utility, regulatory evolution, and the commercial dynamics that influence adoption.

As the field evolves, stakeholders from device manufacturers to healthcare providers and research institutions must navigate complex tradeoffs between performance, cost, and interoperability. Throughout this report, emphasis is placed on where multimodal imaging delivers differentiated clinical value, the operational considerations required for effective deployment, and the partnerships that are proving most productive. The introduction sets expectations for the subsequent sections, highlighting how technical advances translate into clinical benefits and what leaders should evaluate when assessing investments and collaborations.

A delineation of the major technological, regulatory, and commercial inflection points reshaping multimodal imaging adoption and clinical workflows

The landscape of multimodal imaging is undergoing transformative shifts driven by technological innovation, increasing demand for precision diagnostics, and an expanding role for data-driven interpretation. Hardware improvements such as higher-resolution detectors, compact multimodality scanners, and hybrid systems are enabling clinicians to acquire richer datasets in single imaging sessions. Concurrently, software advancements-spanning AI-enabled image reconstruction, quantitative biomarkers, and integrated PACS workflows-are unlocking new diagnostic insights and reducing interpretation variability.

Regulatory pathways and reimbursement frameworks are also adapting, encouraging vendors and health systems to demonstrate clinical utility and cost-effectiveness. These shifts are prompting new commercial models where services and software subscriptions complement capital purchases, and collaborations between device makers, academic centers, and imaging networks become central to accelerating evidence generation. The combined effect is a landscape where rapid iteration of both hardware and software is balanced against the need for validated clinical outcomes, creating opportunities for those who can deliver interoperable, user-centric solutions and clear evidence of improved patient management.

An examination of how recent U.S. tariff dynamics have compelled supply chain realignment, procurement adaptation, and strategic sourcing in the medical imaging sector

Tariff policy changes can introduce material frictions into global medical device supply chains, raising procurement costs and reshaping sourcing strategies. In the United States context, recent tariff adjustments have influenced import decisions for imaging hardware, components, and accessories, prompting manufacturers to reassess production footprints, supplier contracts, and inventory management. These policy shifts often accelerate conversations around nearshoring, regional manufacturing hubs, and dual-sourcing strategies designed to mitigate exposure to trade-related cost volatility.

From a practical perspective, healthcare providers and distribution partners have responded by revisiting procurement timelines, consolidating orders, and negotiating total-cost-of-ownership arrangements that encompass service and consumables. For vendors, tariff-induced cost pressures have reinforced the importance of value-based pricing, bundled service offerings, and stronger local partnerships to preserve market access. Moving forward, organizations that proactively redesign supply chains, engage in scenario planning for tariff fluctuations, and pursue flexible manufacturing and distribution arrangements will be better positioned to sustain market presence and protect margins.

An integrated segmentation perspective linking components, modalities, applications, and end-user profiles to reveal differentiated adoption pathways and value drivers

A granular segmentation analysis illuminates how demand drivers and deployment considerations vary when the market is viewed through multiple analytical lenses. Based on Component, market is studied across Hardware, Services, and Software; this classification highlights distinct investment cycles and procurement behaviors, where capital expenditures for advanced hardware co-exist with recurring revenue models tied to services and software licensing. Hardware decisions prioritize throughput, image quality, and integration compatibility, while services and software investments emphasize lifecycle support, analytics capability, and interoperability with clinical IT systems.

Based on Modality, market is studied across PET CT, PET MR, and SPECT CT; modality-specific dynamics influence clinical workflows, facility requirements, and cross-disciplinary collaboration. PET CT remains central for many oncology pathways where combined metabolic and anatomic information is critical, PET MR offers advantages in soft-tissue characterization and neurologic applications, and SPECT CT provides a cost-effective approach for many cardiovascular and functional imaging uses. Based on Application, market is studied across Cardiovascular, Neurology, and Oncology; each application category places different value on quantitative biomarkers, spatial resolution, and repeatability, which in turn informs procurement priorities and evidence requirements. Finally, Based on End User, market is studied across Academic Institutes, Diagnostic Imaging Centers, Hospitals, and Research Institutes; the end-user profile shapes budget cycles, clinical trial participation, and the appetite for early adoption versus validated deployment. Taken together, these segmentation lenses provide a composite view of where innovation yields the most clinical and operational advantage and where tailored commercial strategies will be most effective.

A regional analysis outlining how Americas, EMEA, and Asia-Pacific healthcare structures and policy landscapes drive differentiated adoption patterns and partnership models

Regional dynamics play a pivotal role in shaping technology adoption, reimbursement policy, and strategic partnerships within the multimodal imaging ecosystem. In the Americas, the market structure often reflects a combination of advanced tertiary centers driving clinical innovation and regional imaging networks optimizing access and throughput. Investment priorities are frequently guided by reimbursement models, hospital consolidation trends, and the emergence of diagnostic hubs that centralize high-cost imaging services to improve utilization and evidence generation.

In Europe, Middle East & Africa, heterogeneity across healthcare systems leads to varied adoption timelines, with some markets favoring early access programs at academic centers while others emphasize cost containment and centralized procurement. Regulatory harmonization efforts and cross-border clinical collaborations are influencing how vendors design market entry strategies. In the Asia-Pacific region, rapid infrastructure expansion, growing clinical research capacity, and increasing investments in digital health are accelerating uptake of advanced modalities. Local manufacturing, public-private partnerships, and targeted training programs are catalyzing adoption, while unique patient demographics and disease burdens create compelling use cases for specific applications. Across all regions, successful strategies align product design with local clinical priorities, reimbursement realities, and partner ecosystems to achieve sustainable adoption.

A strategic overview of how incumbent vendors and agile specialists are competing through integrated hardware, software, and service models to capture clinical and commercial value

Competitive dynamics in multimodal imaging are characterized by a blend of established platform providers and emerging specialists that bring focused innovations in detector design, reconstruction algorithms, and clinical software. Leading companies are investing in integrated offerings that combine robust hardware performance with advanced analytics and cloud-enabled services, while newer entrants often differentiate on modularity, cost-efficiency, or novel AI-driven capabilities. Strategic alliances between device manufacturers, software developers, and clinical networks are increasingly common, enabling faster validation and deployment of integrated solutions.

In addition to product innovation, companies are competing on service delivery models, including subscription-based software, managed services for imaging operations, and value-based arrangements tied to clinical outcomes. Intellectual property around quantitative biomarkers, reconstruction techniques, and image analysis pipelines is a critical moat, but companies that prioritize open interoperability and clinician-centered design are gaining traction within health systems. Mergers, targeted acquisitions, and collaborative research agreements remain primary mechanisms to expand clinical reach and fill technological gaps, underscoring the need for pragmatic partnerships that accelerate evidence generation and commercial uptake.

Actionable strategic guidance for vendors, providers, and investors to prioritize clinical value, supply chain resilience, and commercial models that accelerate adoption

Industry leaders should align innovation priorities with clinical impact, focusing on measurable improvements in diagnostic accuracy, workflow efficiency, and patient experience. Investment decisions must balance capital equipment performance with the long-term value of software platforms and service ecosystems that enable continuous improvement and scalability. Partnering with leading academic centers and clinical trial networks can accelerate evidence generation, supporting faster regulatory acceptance and payer engagement.

Operationally, organizations should pursue supply chain resilience through diversified sourcing, modular product architectures, and flexible service delivery models that reduce dependence on single suppliers or geographies. Commercial strategies should emphasize outcomes-oriented value propositions, bundled solutions that lower administrative friction, and tiered pricing structures that accommodate varied end-user budgets. Finally, leaders must invest in workforce training and change management to ensure that technological upgrades translate into sustained improvements in clinical practice and patient care.

A transparent description of the multi-source research approach combining clinical interviews, technical literature, and regulatory analysis to ensure robust evidence synthesis

This research synthesis draws on a multi-source methodology that integrates technical literature review, policy and regulatory analysis, and qualitative interviews with clinical and commercial stakeholders. Primary insights were derived from structured discussions with imaging specialists, hospital procurement leaders, and service providers, complemented by an examination of peer-reviewed studies describing clinical performance and implementation outcomes. Secondary sources included regulatory guidance documents, technology white papers, and vendor technical specifications to validate device capabilities and interoperability claims.

Analytical rigor was enhanced through cross-validation of qualitative findings against documented clinical use-cases and published methodological studies. The approach prioritized triangulation, ensuring that commercial observations were grounded in clinical realities and that technical assertions were supported by reproducible evidence. Limitations are acknowledged where access to proprietary clinical datasets or longitudinal utilization studies was restricted, and recommendations reflect conservative interpretation where evidence remains emergent. Transparency in methodology enables stakeholders to understand the provenance of insights and to request tailored analyses aligned with their strategic questions.

A concise synthesis emphasizing interoperability, clinical validation, and strategic partnerships as the essential pillars for long-term success in multimodal imaging

The conclusion synthesizes the primary messages: multimodal imaging is maturing into a clinically consequential and commercially dynamic domain that demands coordinated innovation across hardware, software, and service layers. Technologies that deliver quantifiable clinical utility, enhance workflow efficiency, and integrate with broader healthcare IT ecosystems will lead adoption. Equally important are pragmatic commercial models and partnerships that enable evidence generation, training, and sustainable financing for deployment across diverse care settings.

Moving forward, stakeholders who emphasize interoperability, clinician-centered design, and resilient supply chains will be best positioned to translate technological promise into improved patient outcomes. Continued collaboration among vendors, clinical researchers, payers, and policymakers will be essential to align incentives, validate new applications, and ensure equitable access. The conclusion underscores that strategic choices made today in product development, evidence generation, and market engagement will determine who captures the long-term clinical and commercial benefits of multimodal imaging.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multimodal Imaging Market, by Component

  • 8.1. Hardware
  • 8.2. Services
  • 8.3. Software

9. Multimodal Imaging Market, by Modality

  • 9.1. PET CT
  • 9.2. PET MR
  • 9.3. SPECT CT

10. Multimodal Imaging Market, by Application

  • 10.1. Cardiovascular
  • 10.2. Neurology
  • 10.3. Oncology

11. Multimodal Imaging Market, by End User

  • 11.1. Academic Institutes
  • 11.2. Diagnostic Imaging Centers
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Multimodal Imaging Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Multimodal Imaging Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Multimodal Imaging Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Multimodal Imaging Market

16. China Multimodal Imaging Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bruker Corporation
  • 17.6. Canon Medical Systems Corporation
  • 17.7. Carl Zeiss AG
  • 17.8. Fujifilm Holdings Corporation
  • 17.9. General Electric Company
  • 17.10. Koninklijke Philips N.V.
  • 17.11. Mediso Medical Imaging Systems Ltd.
  • 17.12. MR Solutions Ltd.
  • 17.13. PerkinElmer, Inc.
  • 17.14. Siemens Healthineers AG
  • 17.15. United Imaging Healthcare Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTIMODAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTIMODAL IMAGING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MULTIMODAL IMAGING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MULTIMODAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MULTIMODAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MULTIMODAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY HARDWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY PET CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY PET CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY PET CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY PET MR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY PET MR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY PET MR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY SPECT CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY SPECT CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY SPECT CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS MULTIMODAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA MULTIMODAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA MULTIMODAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE MULTIMODAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST MULTIMODAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 73. MIDDLE EAST MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA MULTIMODAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 78. AFRICA MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC MULTIMODAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN MULTIMODAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 89. ASEAN MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GCC MULTIMODAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GCC MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 94. GCC MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 95. GCC MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. GCC MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION MULTIMODAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPEAN UNION MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS MULTIMODAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 104. BRICS MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. G7 MULTIMODAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. G7 MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 109. G7 MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 110. G7 MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. G7 MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NATO MULTIMODAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NATO MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 114. NATO MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 115. NATO MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. NATO MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MULTIMODAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES MULTIMODAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 120. UNITED STATES MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 121. UNITED STATES MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. UNITED STATES MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA MULTIMODAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA MULTIMODAL IMAGING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 125. CHINA MULTIMODAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 126. CHINA MULTIMODAL IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. CHINA MULTIMODAL IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)